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H3K27me3 as a biomarker in diagnosing H3F3A K27M 
mutations. Moreover, cases that stained positive for H3.3 
K27M showed a significantly poor prognosis compared to 
corresponding negative tumors. These results suggest that 
immunohistochemical detection of H3.3 K27M is a sensi-
tive and specific surrogate for the H3F3A K27M mutation 
and defines a prognostically poor subset of pediatric GBM.
Keywords Pediatric glioblastoma · H3F3A mutation · 
K27M mutation · H3K27me3 · Diagnostic biomarker · 
Prognosis · Methylation · Epigenetics
Introduction
Genomic sequencing has substantially enhanced the under-
standing of the genetics and molecular biology of brain 
tumors. Many new driver mutations have been identified 
that will help in elucidating the pathogenesis of these dis-
orders. Consequently, this has led to a shift in the paradigm 
Abstract Pediatric glioblastomas (GBM) are highly 
aggressive and lethal tumors. Recent sequencing studies 
have shown that ~30 % of pediatric GBM and ~80 % of 
diffuse intrinsic pontine gliomas show K27M mutations in 
the H3F3A gene, a variant encoding histone H3.3. H3F3A 
K27M mutations lead to global reduction in H3K27me3. 
Our goal was to develop biomarkers for the histopathologic 
detection of these tumors. Therefore, we evaluated the 
utility of measuring H3K27me3 global reduction as a his-
topathologic and prognostic biomarker and tested an anti-
body directed specifically against the H3.3 K27M mutation 
in 290 samples. The study cohort included 203 pediatric 
(including 38 pediatric high-grade astrocytomas) and 38 
adult brain tumors of various subtypes and grades and 49 
non-neoplastic reactive brain tissues. Detection of H3.3 
K27M by immunohistochemistry showed 100 % sensitiv-
ity and specificity and was superior to global reduction in 
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of how we approach the diagnosis of brain tumors, where 
genomic information is integral and complementary to his-
topathologic diagnoses.
Sequencing studies of pediatric high-grade gliomas 
[including glioblastomas, anaplastic astrocytomas and dif-
fuse intrinsic pontine gliomas (DIPG)] have shown recur-
rent mutations in the H3F3A gene (encoding the histone 
H3.3). Mutations were noted at position 27, where the 
lysine residue is replaced by methionine (K27M) or at 
position 34, the glycine residue is replaced by arginine or 
valine (G34R/V) [3, 4, 9, 10, 13, 17, 18, 24]. A small per-
centage of DIPG cases also showed HIST1H3B encoding 
the histone H3.1 where the lysine residue at position 27 is 
replaced by methionine (K27M) [3, 24]. Since lysine resi-
dues on histone tails are subject to post-translational modi-
fications, we and others have shown that the H3F3A K27M 
mutation results in global reduction in H3K27me3 [2, 6, 15, 
22]. H3K27 is trimethylated by the polycomb repressive 
complex 2 (PRC2) to generate the repressive H3K27me3 
mark. Enhancer of zest 2 (EZH2) is the main methyltrans-
ferase enzyme contained in this complex that is responsible 
for trimethylation of H3K27. The H3 K27M mutant pro-
tein binds to EZH2 to inhibit its methyltransferase activ-
ity, resulting in a global reduction of H3K27me3 [2, 15]. 
Moreover, these tumors also show a DNA hypomethylation 
phenotype [2, 12, 18]. The mechanisms by which H3F3A 
mutations contribute to the pathogenesis of gliomas are not 
clearly understood and are currently being investigated.
Current methodology of assessing these mutations is 
based on sequencing studies. While time consuming and 
tedious, this methodology may not be readily accessible 
to all laboratories. Thus, we sought to evaluate histopatho-
logic biomarkers for evaluating H3F3A K27M mutations 
to aid in establishing the diagnosis of these tumors using 
immunohistochemistry (IHC), a tool that is readily avail-
able to most pathology practices. To this end, we assessed 
if detection of global reduction of H3K27me3 by immuno-
histochemical staining could be used as a molecular sur-
rogate for H3F3A K27M mutations. We compared global 
reduction in H3K27me3 with a novel antibody specifically 
targeting H3.3 K27M mutations. Western blot analysis 
showed that the antibody raised against the N-terminal of 
the H3.3 K27M protein was specific for the mutation [15]. 
We used IHC to detect overall levels of H3K27me3 in 290 
samples consisting of pediatric brain tumors, adult brain 
tumors and non-neoplastic brain tissues. Our goal was to 
determine the sensitivity and specificity of both markers in 
diagnosing H3F3A K27M mutations. Our results indicate 
that antibody directed against H3.3 K27M is superior to 
global reduction of H3K27me3 as a marker in diagnosing 
H3F3A K27M mutant GBM with 100 % sensitivity, speci-
ficity and positive and negative predictive values and can be 
used as a prognostic indicator.
Methods
Cohort
Tissue samples were obtained from the Departments of 
Pathology and Laboratory Medicine from Children’s Hos-
pital of Philadelphia, Children’s Hospital Los Angeles and 
the University of San Francisco after institutional review 
board approval from all institutions. All identifiers from 
cases were removed prior to analysis. 241 cases were con-
tained in previously well-characterized tissue microarrays 
(TMA) and only tissue cores containing more than 95 % 
tumor were included in this analysis [5, 19, 21–23]. Pedi-
atric brain tumors consisted of 36 pilocytic astrocytomas 
(Pilo, WHO grade I), 5 subependymal giant cell astrocy-
toma (SEGA, grade I), 9 dysembryoplastic neuroepithelial 
tumors (DNET, grade I), 17 gangliogliomas (GG, grade I), 
16 grade II astrocytomas (Astro, 14 fibrillary astrocytomas, 
1 pilomyxoid astrocytoma, and 1 pleomorphic xanthoastro-
cytoma, all grade II), 5 oligodendrogliomas (Oligo, grade 
II), 10 meningiomas (Men, grade I), 24 medulloblastomas 
(MB, grade IV) 26 atypical teratoid/rhabdoid tumors (AT/
RT, grade IV), 3 craniopharyngiomas (CP, grade I), 11 
choroid plexus papillomas (CPP, grade I), 3 neurocytomas 
(NC, grade II) and 38 high-grade astrocytomas including 4 
anaplastic astrocytomas (AA, grade III) and 34 glioblasto-
mas (GBM, grade IV) (collectively referred to as pediatric 
GBM for simplicity). Of the 203 pediatric tumors, we have 
previously reported H3K27me3 in 40 cases including 20 
pediatric GBMs [22]. Adult tumors consisted of 4 pilocytic 
astrocytomas (PA, grade I), 2 gangliogliomas (GG, grade I), 
3 diffuse astrocytomas (DA, grade II), 8 anaplastic astrocy-
tomas (AA, grade III), 3 oligodendrogliomas (OD, grade 
II), 5 anaplastic oligodendrogliomas (AO, grade III) and 13 
glioblastomas (GBM, grade IV). The demographics of these 
cases have been reported elsewhere [5, 19, 21–23]. Non-
neoplastic tissues were studied as full slides and included 
normal brain (n = 3), vascular malformation (n = 4), 
ischemia (n = 4), hemorrhage (n = 5), CNS malformations 
(n = 5), infectious disease (n = 8), vasculitis (n = 5), hip-
pocampal sclerosis (n = 5), demyelinating disorders (n = 5) 
and metastatic tumors (n = 5). Two independent neuro-
pathologists reviewed all cases in a blinded manner.
Immunohistochemistry and automated scoring
Immunohistochemical studies were performed as previously 
published [22]. In brief, immunostaining was performed using 
the Discovery XT processor (Ventana Medical Systems). A 
commercially available rabbit polyclonal antibody that recog-
nizes the N-terminus of Histone H3.3, K27M mutant protein 
(anti-H3 K27M, #ABE419, Millipore, Billercia, MA, USA; 
0.5 μg/mL) was used [15]. To detect H3K27me3, a rabbit 
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polyclonal anti-H3K27me3 (07-449, Millipore, Billercia, 
MA, USA; 1 μg/mL) was used as previously described [22]. 
Tissue sections were blocked for 30 min in 10 % normal goat 
serum in 2 % BSA in PBS. Sections were incubated for 5 h 
with the anti-H3K27me3 or anti-H3.3 K27M antibodies. Tis-
sue sections were then incubated for 60 min with biotinylated 
goat anti-rabbit IgG (Vector labs, PK6101) at 1:200 dilution. 
Blocker D, Streptavidin-HRP and DAB detection kit (Ven-
tana Medical Systems) were used according to the manufac-
turer instructions. To ensure uniformity of IHC, we compared 
staining in 40 cases contained in tissue microarrays with 
their corresponding full sections (40 randomly selected cases 
including 20 pediatric GBM) selected from the same blocks 
that were used to generate the TMA for both H3K27me3 and 
H3.3 K27M. For both markers, staining results were identi-
cal in tissue microarrays and full sections. Additionally, we 
evaluated both H3K27me3 and H3.3 K27M in full sections 
for all 38 cases of pediatric high-grade astrocytomas.
H3K27me3 and H3.3 K27M stained tumor sections were 
scored/quantified by automated image processing software 
(data are presented in Fig. 2). Automated scoring was per-
formed by scanning each slide using a Pannoramic Flash 
250 scanner (Perkin Elmer, Waltham, MA, USA). Scanned 
slides were viewed through the Pannoramic viewer software 
program (3D Histech, Waltham, MA, USA). An individual 
blinded to the experimental design captured JPEG images 
from each core or full section (circular area of 315 cm2 corre-
sponding to the entire core or randomly chosen equivalent area 
from full sections) at 10× magnification on the Pannoramic 
viewer software program. Quantification of immunostaining 
on each JPEG was conducted using an automated analysis 
program with Matlab’s image processing toolbox based on 
previously described methodology [22]. The algorithm used 
color segmentation with RGB color differentiation, K-means 
clustering and background–foreground separation with Otsu’s 
thresholding. To arrive at a score the number of extracted pix-
els was multiplied by their average intensity for each core. 
The final score for a given case and marker was calculated by 
averaging the score of two randomly chosen areas for each full 
section or two core tumor samples or for each case.
H3F3A gene sequencing
Sanger sequencing for H3F3A coding exons was performed 
as previously described [22]. Paraffin-embedded forma-
lin-fixed (FFPE) blocks from GBMs were used to extract 
Fig. 1  Comparison of immu-
nostaining for H3K27me3 and 
H3.3 K27M in wild-type and 
H3F3A K27M mutant pediatric 
GBM. a, b Representative 
images from a H3F3A K27M 
wild-type tumor, H3K27me3 
(40×, a) and H3.3 K27M 
(40×, b). c–f. Representative 
images from two different 
H3F3A K27M mutant tumors, 
H3K27me3 (40×, c and 60×, 
e) and H3.3 K27M (40×, d and 
60×, f). Arrowheads indicate 
endothelial cells in blood ves-
sels
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genomic DNA was extracted from two 10 μ slices. The For-
mapure kit (Agencourt, Beverly, MA, USA) was used accord-
ing to manufacturers’ method in a 96-well format in a semi-
automated fashion using primers previously standardized 
[22]. M13 tails were added to facilitate Sanger sequencing. 
PCR reactions were set up in 384 well plates, in a Beckman 
Coulter Biomek® FX, and run in a Duncan DT-24 water bath 
thermal cycler, with 10–40 ng of genomic DNA as tem-
plate, HotStart Taq (Kapa Biosystems, Woburn, MA, USA), 
250 μM dNTPs, 1× PCR buffer, 6 % DMSO and 0.2 μM 
primers. A “touchdown” PCR method was used, which con-
sisted of: 1 cycle of 95 °C for 5 min; 3 cycles of 95 °C for 
30 s, 64 °C for 30 s, 72 °C for 60 s; 3 cycles of 95 °C for 
30 s, 62 °C for 30 s, 72 °C for 60 s; 3 cycles of 95 °C for 30 s, 
60 °C for 30 s, 72 °C for 60 s; 37 cycles of 95 °C for 30 s, 
58 °C for 30 s, 72 °C for 60 s; 1 cycle of 70 °C for 5 min. 
Amplified DNA was purified using AMPure (Agencourt 
Biosciences, Beverly, MA, USA). The purified PCR reac-
tions were split into two, and sequenced bidirectionally with 
M13 forward and reverse primer and Big Dye Terminator Kit 
v.3.1 (Applied Biosystems, Foster City, CA, USA), at Agen-
court Biosciences. Dye terminators were removed using the 
CleanSEQ kit (Agencourt Biosciences), and sequence reac-
tions were run on ABI PRISM 3730xl sequencing apparatus 
(Applied Biosystems, Foster City, CA, USA). The sequences 
were analyzed using an automated mutation detection pipe-
line developed by the MSKCC Bioinformatics Core.
Statistical analysis
Statistical analyses were performed in consultation with the 
Memorial Sloan-Kettering biostatistics core. SPSS (version 
21, IBM, Chicago, IL, USA) and Prism (version 5, La Jolla, 
CA, USA) were used to analyze data. All statistical tests were 
two sided. Statistical significance was set at the 0.05 level. 
Student’s t test was used to compare H3K27me3 or H3.3 
K27M levels between H3F3A K27M mutant and wild-type 
tumors. The log-rank (Mantel–Cox) test was used to examine 
the association of H3.3 K27M positivity with overall survival. 
Multivariate survival analysis was performed using the Cox 
proportional hazards model. Differences were considered sig-
nificant when p < 0.05 (95 % confidence intervals).
Diagnostic performance measures including sensitivity, 
specificity, positive predictive value (PPV) and negative 
Fig. 2  Quantification of H3K27me3 and H3.3 K27M immunostain-
ing in adult and pediatric brain tumors and survival analyses in pedi-
atric high-grade gliomas. a, c Quantification of H3K27me3 (a) and 
H3.3 K27M (c) IHC in pediatric brain tumors. ***p < 0.0001. Pilo 
pilocytic astrocytoma, SEGA subependymal giant cell astrocytoma, 
Astro grade II astrocytoma, OD oligodendroglioma, DNET dysem-
bryoplastic neuroepithelial tumor, GG ganglioglioma, NC neurocy-
toma, MEN meningioma, CP craniopharyngioma, AT/RT atypical 
teratoid/rhabdoid tumor, CPP choroid plexus papilloma, MB medul-
loblastoma, K27M H3F3A K27M mutant GBMs, WT GBMs without 
H3F3A K27M mutations. b Quantification of H3K27me3 (left Y-axis) 
and H3.3 K27M (right Y-axis) in adult brain tumors. Pilo pilocytic 
astrocytoma, DA diffuse astrocytoma, GG ganglioglioma, AA ana-
plastic astrocytomas, GBM glioblastoma, OD oligodendroglioma, 
AO anaplastic oligodendrogliomas. d Kaplan–Meier survival analy-
ses between H3.3 K27M immunopositive (red line) and H3.3 K27M 
immunonegative (black line) pediatric GBMs (see also Table 2)
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predictive value (NPV) for each marker were calculated 
using standard statistical methodology [16]. Sensitivity is 
defined as the probability of a positive test result (immu-
nopositive) given that the subject has H3F3A K27M muta-
tions. Specificity is defined as the probability of a negative 
test result (immunonegative) given that the sample does 
not bear the mutation. PPV is defined as the percentage of 
patients with a positive test (immunopositive) who actually 
bear H3F3A K27M mutations and NPV is defined as nega-
tive test (immunonegative) in patients who do not have the 
mutation.
Results
Assessment of H3K27me3 immunoreactivity in pediatric 
and adult brain tumors and non-neoplastic brain tissue 
samples
H3K27me3 was evaluated using IHC with automated 
scoring in a cohort of 241 brain tumors consisting of 203 
pediatric and 38 adult brain tumors. The cohort consisted 
of 38 pediatric high-grade astrocytomas and we used 
Sanger sequencing as previously described to determine the 
histone mutational status in all these tumors [22]. Sanger 
sequencing revealed 12 H3F3A K27M mutant tumors and 
1 H3F3A G34R tumor; no HIST1H3B mutations were 
detected (Supplementary Table S1). Of these 38 tumors, 
one H3F3A wild-type tumor recurred.
H3K27me3 was assessed in all tumor samples. Global 
reduction in H3K27me3 was observed in all 12 H3F3A 
K27M mutant tumors while H3K27me3 was not glob-
ally reduced in tumors without the mutation including 
the H3F3A G34R mutant tumor (Figs. 1, 2; Supplemen-
tary Figure S1 and Tables S1 and S2). H3K27me3 stain-
ing was highest in medulloblastomas (Figs. 2, 3). AT/
RT showed a variable pattern where five (5/26) cases 
showed a reduction in H3K27me3 staining (Fig. 3; Sup-
plementary Figure S2). Relatively lower H3K27me3 val-
ues in tumors such as DNET, GG and pediatric pilocytic 
astrocytomas were not due to reduced H3K27me3 in 
tumor cells but due to relatively lower cellularity of these 
Fig. 3  Comparison of 
H3K27me3 and H3.3 K27M 
in CNS embryonal tumors. a, 
b Representative images of 
H3K27me3 (40×, a) and H3.3 
K27M (40×, b) in medullo-
blastoma. c, d Representative 
images of H3K27me3 (40×, 
c) and H3.3 K27M (40×, d) 
in an AT/RT case with high 
H3K27me3. e , f Representative 
images of H3K27me3 (40×, 
e) and H3.3 K27M (40×, f) 
in subset of AT/RT with low 
H3K27me3
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tumors (Figure S3). The other pediatric tumors as well 
as adult brain tumors showed strong nuclear H3K27me3 
reactivity (Figs. 4, 5). We also evaluated H3K27me3 in 
the normal brain and non-neoplastic brain tissues includ-
ing tissues with infarction, hemorrhage, cortical malfor-
mations, hippocampal sclerosis, infections, vascular mal-
formations and hippocampal sclerosis. H3K27me3 was 
ubiquitously present and showed strong nuclear staining 
in all cases (Fig. 6).
H3.3 K27M specific antibody shows positivity in H3F3A 
K27M mutant tumors
We next performed immunohistochemistry using an anti-
body specifically generated against the N-terminus of 
the histone mutant H3.3 K27M protein [15] in all tissue 
samples. H3.3 K27M showed strong nuclear staining in 
more than 80 % of tumor cells in all H3F3A K27M mutant 
tumors, but not in samples without the mutation (Figs. 1, 
Fig. 4  Comparison of 
H3K27me3 and H3.3 K27M 
in pediatric brain tumors. a, 
b Representative images of 
H3K27me3 (40×, a) and H3.3 
K27M (40×, b) in choroid 
plexus papilloma (CPC). c, 
d Representative images of 
H3K27me3 (40×, c) and H3.3 
K27M (40×, d) in meningioma. 
e, f Representative images of 
H3K27me3 (40×, e) and H3.3 
K27M (40×, f) in craniophar-
yngioma. g, h Representative 
images of H3K27me3 (40×, 
g) and H3.3 K27M (40×, h) in 
neurocytoma
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2). Endothelial cells within the tumor did not show posi-
tivity, suggesting that staining was specific to tumor cells 
(Fig. 1). Moreover, the case with H3F3A G34R mutation 
did not show any immunoreactivity (Supplementary Fig-
ure S1). H3.3 K27M did not show nuclear staining and 
was significantly lower in the rest of the H3F3A wild-
type high-grade gliomas and all other pediatric and adult 
and brain tumor samples and non-neoplastic brain tissues 
(Figs. 2, 3, 4, 5, 6, S3; Supplementary Table S1). Occa-
sional scattered cells in reactive tissues, other pediatric 
brain tumors and wild-type cases, showed faint, granular, 
cytoplasmic staining that was interpreted as non-specific 
staining as this was similar in non-neoplastic and neoplas-
tic tissues.
Since H3F3A K27M mutant tumors are thought to have 
a worse prognosis than wild-type tumors [3, 13, 18], we 
evaluated the prognostic utility of the H3.3 K27M antibody. 
Overall survival was significantly lower in H3.3 K27M 
positive tumors compared to H3.3 K27M negative tumors 
(Fig. 2c, Log-rank (Mantel–Cox) test, hazards ratio = 4.97, 
p = 0.015). Multivariate analysis using the Cox propor-
tional hazards model showed that H3.3 K27M positivity 
was a significant prognostic factor (p = 0.025), but not age, 
sex, grade or location (Fig. 2c; Table 2). These data suggest 
Fig. 5  Comparison of 
H3K27me3 and H3.3 K27M in 
adult brain tumors. a, b Repre-
sentative images of H3K27me3 
(40×, a) and H3.3 K27M (40×, 
b) in diffuse astrocytoma. c, 
d Representative images of 
H3K27me3 (40×, c) and H3.3 
K27M (40×, d) in anaplas-
tic oligodendroglioma e and 
f. Representative images of 
H3K27me3 (40×, e) and H3.3 
K27M (40×, f) in anaplastic 
astrocytoma. g, h Repre-
sentative images of H3K27me3 
(40×, g) and H3.3 K27M (40×, 
h) in adult GBM
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Fig. 6  Comparison of 
H3K27me3 and H3.3 K27M 
in non-neoplastic brain tissues. 
a, b Representative images 
of H3K27me3 (5×, a, inset 
40×) and H3.3 K27M (5×, 
b, inset 40×) in focal cortical 
dysplasia (FCD). c, d Repre-
sentative images of H3K27me3 
(10×, c, inset 40×) and H3.3 
K27M (10×, d, inset 40×) in 
hippocampal (Hip) sclerosis. 
e, f Representative images 
of H3K27me3 (5×, e, inset 
40×) and H3.3 K27M (5×, 
f, inset 40×) in hemorrhage. 
g, h Representative images of 
H3K27me3 (5×, g, inset 40×) 
and H3.3 K27M (5×, h, inset 
40×) in abscess, inset shows 
abscess wall. i, j Representa-
tive images of H3K27me3 (5×, 
i, inset 40×) and H3.3 K27M 
(5×, j, inset 40×) in infarction, 
inset shows macrophages
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that immunohistochemical assessment of H3F3A K27M 
mutational status is sufficient for prognostication.
Comparison of sensitivity and specificity of H3K27me3 
and H3.3 K27M positivity in diagnosing H3F3A K27M 
mutant tumors
We compared data from both markers to evaluate sensi-
tivity, specificity, positive predictive and negative predic-
tive values in our tissue samples. Immunohistochemistry 
for H3.3 K27M was highly sensitive and specific (100 %) 
with 100 % PPV and NPV (Table 2). Global reduction 
of H3K27me3, while still sensitive (100 %) and specific 
(98 %), showed an overall lower PPV of 70 % because of 
lowered H3K27me3 in 5/26 AT/RT cases (Table 1; Sup-
plementary Table 2), suggesting that H3.3 K27M detection 
may be the preferable diagnostic biomarker.
Discussion
Brain tumors constitute the most common solid malig-
nancy of the pediatric age group. Amongst these, glioblas-
tomas and DIPGs have a dismal prognosis. Recent genomic 
studies of pediatric high-grade gliomas and DIPGs have 
revealed mutations in histone variant genes encoding 
histone proteins, Activin A receptor, type I (ACVR1) and 
protein phosphatase 1D (PPM1D) bringing new insights 
into the pathogenesis of these malignancies [4, 8, 13, 17, 
18, 20, 24–26]. Histone mutations involve H3F3A (encod-
ing histone H3.3) at the K27 and G34 positions in pediat-
ric glioblastomas (~30 %) and DIPG (~80 %) and more 
rarely HIST1H3 (encoding H3.1) K27 mutations [4, 9, 10, 
13, 17, 18, 24]. Interestingly, H3F3A K27M mutations are 
also noted in thalamic gliomas in young adults [1]. H3F3A 
K27M results in global reduction of H3K27me3 [2, 6, 15, 
22]. The mutant K27M inhibits the activity of the PRC2 
enzymatic complex by interacting with EZH2, the compo-
nent of the PRC2 complex that methylates H3K27 [2, 15]. 
Clinically, these tumors are characterized by worse progno-
sis, predilection for younger age groups and more frequent 
midline CNS location [7, 17]. Further, newer experimental 
therapies targeting enzymes that mediate DNA and histone 
methylation are also emerging [11]. These factors under-
score the urgent and unmet need to identify H3F3A K27M 
mutant tumors in day-to-day surgical neuropathologic prac-
tice in a rapid, accurate and cost-effective manner.
To address this, we evaluated two potential biomarkers 
to recognize H3F3A K27M mutant tumors using immu-
nohistochemistry, a tool that is readily accessible to most 
pathology practices. Recent sequencing analyses of 338 
pediatric brain tumors (including many of the varieties of 
pediatric brain tumors included in our cohort) have shown 
that histone H3F3A K27M mutations occur exclusively in 
pediatric astrocytic tumors [10]. Thus, we used a compre-
hensive cohort of pediatric and adult tumor samples and 
non-neoplastic brain tissues negative controls to assess the 
specificity and sensitivity of the two tested biomarkers.
First, we assessed the utility of global reduction in 
H3K27me3 as a means to identify these tumors. Consistent 
with what we and others have previously reported, we iden-
tified a global reduction in H3K27me3 in tumors bearing 
H3F3A K27M mutations compared to tumors without the 
mutation (Figs. 1, 2) [2, 6, 15, 22]. These data suggest that 
lowered H3K27me3 may be a potential biomarker. However, 
we found that 5/26 AT/RT cases also showed global reduc-
tion in H3K27me3 resulting in a net positive predictive value 
of only 70 % (Table 1). Since AT/RT are characterized by 
SMARCB1 mutations, but are otherwise genomically silent 
[14], we compared the expression of EZH2 in cases with 
or without reduction in H3K27me3. We found that EZH2 
expression was lower in AT/RTs with reduced H3K27me3, 
possibly explaining reduced H3K27me3 in the subset of these 
tumors observed in this study (Supplementary Figure S2).
To find a better marker, we used a commercially avail-
able antibody that specifically targets the H3.3 K27M 
mutation [15]. This antibody showed nuclear staining spe-
cifically in tumor cells (Fig. 1). Endothelial cells within 
the tumor stained negative for this antibody, serving as an 
Table 1  Comparison of H3K27me3 and H3.3 K27M in diagnosing 
H3F3A K27M mutant tumors





Table 2  Multivariate Cox regression analysis in pediatric glioblasto-
mas
Age, sex, grade, location, and H3.3 K27M immunopositivity were 
used as variables in Cox proportional hazards model
H3.3 K27M immunopositivity was a significant prognostic factor 
(p = 0.025) but not age, sex, grade or location
Bold font indicates statistical significance (p value below 0.05)
Variable p value Hazards ratio 95 % CI for 
hazards ratio
Lower Upper
Age 0.871 1.006 0.938 1.079
Sex 0.408 1.433 0.611 3.361
Grade 0.932 0.927 0.161 5.324
Location 0.878 0.902 0.243 3.353
H3.3 K27M immunopositive 0.025 3.514 1.17 10.559
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optimal internal control (Fig. 1). We then assessed H3.3 
K27M staining in a total of 290 tissue samples including 
a variety of pediatric and adult brain tumors and non-neo-
plastic brain tissues. We found that H3.3 K27M staining 
was restricted to H3F3A K27M mutant tumors resulting 
in 100 % sensitivity, specificity and positive and negative 
predictive values (Fig. 2; Table 1). Further, immunohisto-
chemistry with H3.3 K27M was sufficient to identify cases 
with a poor prognosis (Fig. 2; Table 2), suggesting that 
prognosis determined by immunostaining is very similar to 
that determined by sequencing studies [13, 18]. Moreover, 
66 % (8/12) of tumors positive for H3.3 K27M and bear-
ing H3F3A K27M mutations were midline in location com-
pared to 23 % (6/26) of tumors negative for H3.3 K27M 
and without the mutation (Supplementary Table S1). Dif-
ference in age at presentation did not differ significantly 
between H3.3 K27M positive tumors with H3F3A K27M 
compared to tumors without these mutations.
We present data from a small cohort of pediatric high-
grade GBM and a comprehensive set of other tumors and 
non-neoplastic tissues showing that immunohistochemical 
staining for H3.3 K27M is a sensitive and specific diag-
nostic and prognostic biomarker to identify H3F3A K27M 
mutant tumors. While a larger cohort of pediatric high-
grade astrocytomas needs to confirm these results, our data 
demonstrate that immunohistochemistry for H3.3 K27M 
can be an effective and reliable tool to diagnose these 
tumors in clinical neuropathology practice.
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